EUVIMEDEUVIMED entdecken
Crossref

EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN

Akira Yuasa, Mitsuhiro Nagano, Yoichi Kamei, Kengo Hatsuyama, Hiroyuki Matsuda, Patrick Hlavacek, Marco Dibonaventura, Kenshi Suzuki

Value in Health · 2026-06 · 29 (6) · S130

DOI: 10.1016/j.jval.2026.03.648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Akira Yuasa und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Yuasa, A., Nagano, M., Kamei, Y., Hatsuyama, K., Matsuda, H., Hlavacek, P., Dibonaventura, M., & Suzuki, K. (2026). EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN. Value in Health, 29(6), S130. https://doi.org/10.1016/j.jval.2026.03.648

Vancouver

Yuasa A, Nagano M, Kamei Y, Hatsuyama K, Matsuda H, Hlavacek P, et al. EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN. Value in Health. 2026;29(6):S130. doi:10.1016/j.jval.2026.03.648

BibTeX
@article{Yuasa2026,
  author = {Yuasa, Akira and Nagano, Mitsuhiro and Kamei, Yoichi and Hatsuyama, Kengo and Matsuda, Hiroyuki and Hlavacek, Patrick and Dibonaventura, Marco and Suzuki, Kenshi},
  title = {EE354 COST-EFFECTIVENESS OF ELRANATAMAB VERSUS PHYSICIAN’S CHOICE OF TREATMENT FOR TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA IN JAPAN},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S130},
  doi = {10.1016/j.jval.2026.03.648}
}
Kostenlos starten →